 "Single dose of Pfizer vaccine cuts Covid-19 spread by half: Study")
A single dose of either the Oxford/ AstraZeneca or Pfizer/BioNTech vaccines have been found to cut Covid-19 transmission rates by up to half, according to a new Public Health England (PHE) study on Wednesday.
Those given a first dose of either of the two vaccines currently being administered by the National Health Service (NHS) and who became infected with SARS-Cov-2 — the coronavirus which causes Covid-19 — three weeks later were between 38 and 49 per cent less likely to pass the virus on than unvaccinated people.
The PHE also found that protection against Covid-19 was seen from about 14 days after vaccination, with similar levels of protection regardless of age of cases or contacts.
“This is further evidence that the vaccine protects you and those around you,” said UK Health Secretary Matt Hancock. The study, yet to be fully peer-reviewed, included more than 57,000 contacts from 24,000 households in which there was a lab-confirmed coronavirus case that had received a vaccination, compared with nearly 1 million contacts of unvaccinated cases.
Contacts were defined as secondary cases of coronavirus if they tested positive two to 14 days after the initial household case. Most of the people in the study were under the age of 60.
The protection against transmission was found on top of the reduced risk of a vaccinated person developing symptomatic infection in the first place, which has previously been found to be 60 to 65 per cent — four weeks after one dose of either vaccine.
Those given a first dose of either of the two vaccines currently being administered by the National Health Service (NHS) and who became infected with SARS-Cov-2 — the coronavirus which causes Covid-19 — three weeks later were between 38 and 49 per cent less likely to pass the virus on than unvaccinated people.
The PHE also found that protection against Covid-19 was seen from about 14 days after vaccination, with similar levels of protection regardless of age of cases or contacts.
“This is further evidence that the vaccine protects you and those around you,” said UK Health Secretary Matt Hancock. The study, yet to be fully peer-reviewed, included more than 57,000 contacts from 24,000 households in which there was a lab-confirmed coronavirus case that had received a vaccination, compared with nearly 1 million contacts of unvaccinated cases.
Contacts were defined as secondary cases of coronavirus if they tested positive two to 14 days after the initial household case. Most of the people in the study were under the age of 60.
The protection against transmission was found on top of the reduced risk of a vaccinated person developing symptomatic infection in the first place, which has previously been found to be 60 to 65 per cent — four weeks after one dose of either vaccine.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%